J K Cements Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 10, 2025, 9:19 pm

Competitors of J K Cements Ltd

All Competitor Stocks of J K Cements Ltd

Quarterly Result

Last Updated: August 1, 2025, 6:45 pm

Below is a detailed analysis of the quarterly data for J K Cements Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 3,353.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,581.00 Cr. (Mar 2025) to 3,353.00 Cr., marking a decrease of 228.00 Cr..
• For Expenses, as of Jun 2025, the value is 2,665.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2,816.00 Cr. (Mar 2025) to 2,665.00 Cr., marking a decrease of 151.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 688.00 Cr.. The value appears to be declining and may need further review. It has decreased from 765.00 Cr. (Mar 2025) to 688.00 Cr., marking a decrease of 77.00 Cr..
• For OPM %, as of Jun 2025, the value is 21.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 21.00%.
• For Other Income, as of Jun 2025, the value is 56.00 Cr.. The value appears strong and on an upward trend. It has increased from 46.00 Cr. (Mar 2025) to 56.00 Cr., marking an increase of 10.00 Cr..
• For Interest, as of Jun 2025, the value is 109.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 113.00 Cr. (Mar 2025) to 109.00 Cr., marking a decrease of 4.00 Cr..
• For Depreciation, as of Jun 2025, the value is 146.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 162.00 Cr. (Mar 2025) to 146.00 Cr., marking a decrease of 16.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 489.00 Cr.. The value appears to be declining and may need further review. It has decreased from 535.00 Cr. (Mar 2025) to 489.00 Cr., marking a decrease of 46.00 Cr..
• For Tax %, as of Jun 2025, the value is 34.00%. The value appears to be increasing, which may not be favorable. It has increased from 32.00% (Mar 2025) to 34.00%, marking an increase of 2.00%.
• For Net Profit, as of Jun 2025, the value is 324.00 Cr.. The value appears to be declining and may need further review. It has decreased from 361.00 Cr. (Mar 2025) to 324.00 Cr., marking a decrease of 37.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 41.99. The value appears to be declining and may need further review. It has decreased from 46.64 (Mar 2025) to 41.99, marking a decrease of 4.65.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: July 22, 2025, 3:34 pm

Growth

Last Updated: September 5, 2025, 8:25 am

Balance Sheet

Last Updated: November 9, 2025, 2:19 pm

Below is a detailed analysis of the balance sheet data for J K Cements Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 77.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 77.00 Cr..
• For Reserves, as of Mar 2025, the value is 6,012.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,290.00 Cr. (Mar 2024) to 6,012.00 Cr., marking an increase of 722.00 Cr..
• For Borrowings, as of Mar 2025, the value is 6,028.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 5,549.00 Cr. (Mar 2024) to 6,028.00 Cr., marking an increase of 479.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 4,564.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,886.00 Cr. (Mar 2024) to 4,564.00 Cr., marking an increase of 678.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 16,682.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14,802.00 Cr. (Mar 2024) to 16,682.00 Cr., marking an increase of 1,880.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 9,519.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,298.00 Cr. (Mar 2024) to 9,519.00 Cr., marking an increase of 221.00 Cr..
• For CWIP, as of Mar 2025, the value is 1,317.00 Cr.. The value appears strong and on an upward trend. It has increased from 464.00 Cr. (Mar 2024) to 1,317.00 Cr., marking an increase of 853.00 Cr..
• For Investments, as of Mar 2025, the value is 601.00 Cr.. The value appears strong and on an upward trend. It has increased from 368.00 Cr. (Mar 2024) to 601.00 Cr., marking an increase of 233.00 Cr..
• For Other Assets, as of Mar 2025, the value is 5,244.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,672.00 Cr. (Mar 2024) to 5,244.00 Cr., marking an increase of 572.00 Cr..
• For Total Assets, as of Mar 2025, the value is 16,682.00 Cr.. The value appears strong and on an upward trend. It has increased from 14,802.00 Cr. (Mar 2024) to 16,682.00 Cr., marking an increase of 1,880.00 Cr..

However, the Borrowings (6,028.00 Cr.) are higher than the Reserves (6,012.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for J K Cements Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 111.44. This value is within the healthy range. It has increased from 102.35 (Mar 24) to 111.44, marking an increase of 9.09.
• For Diluted EPS (Rs.), as of Mar 25, the value is 111.44. This value is within the healthy range. It has increased from 102.35 (Mar 24) to 111.44, marking an increase of 9.09.
• For Cash EPS (Rs.), as of Mar 25, the value is 190.63. This value is within the healthy range. It has increased from 176.34 (Mar 24) to 190.63, marking an increase of 14.29.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 788.01. It has increased from 688.71 (Mar 24) to 788.01, marking an increase of 99.30.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 788.01. It has increased from 688.71 (Mar 24) to 788.01, marking an increase of 99.30.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,537.36. It has increased from 1,495.54 (Mar 24) to 1,537.36, marking an increase of 41.82.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 284.73. This value is within the healthy range. It has decreased from 285.34 (Mar 24) to 284.73, marking a decrease of 0.61.
• For PBIT / Share (Rs.), as of Mar 25, the value is 206.89. This value is within the healthy range. It has decreased from 211.24 (Mar 24) to 206.89, marking a decrease of 4.35.
• For PBT / Share (Rs.), as of Mar 25, the value is 160.71. This value is within the healthy range. It has increased from 151.88 (Mar 24) to 160.71, marking an increase of 8.83.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 112.80. This value is within the healthy range. It has increased from 102.23 (Mar 24) to 112.80, marking an increase of 10.57.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 111.44. This value is within the healthy range. It has increased from 102.35 (Mar 24) to 111.44, marking an increase of 9.09.
• For PBDIT Margin (%), as of Mar 25, the value is 18.52. This value is within the healthy range. It has decreased from 19.07 (Mar 24) to 18.52, marking a decrease of 0.55.
• For PBIT Margin (%), as of Mar 25, the value is 13.45. This value is within the healthy range. It has decreased from 14.12 (Mar 24) to 13.45, marking a decrease of 0.67.
• For PBT Margin (%), as of Mar 25, the value is 10.45. This value is within the healthy range. It has increased from 10.15 (Mar 24) to 10.45, marking an increase of 0.30.
• For Net Profit Margin (%), as of Mar 25, the value is 7.33. This value is within the healthy range. It has increased from 6.83 (Mar 24) to 7.33, marking an increase of 0.50.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.24. This value is below the healthy minimum of 8. It has increased from 6.84 (Mar 24) to 7.24, marking an increase of 0.40.
• For Return on Networth / Equity (%), as of Mar 25, the value is 14.14. This value is below the healthy minimum of 15. It has decreased from 14.73 (Mar 24) to 14.14, marking a decrease of 0.59.
• For Return on Capital Employeed (%), as of Mar 25, the value is 12.51. This value is within the healthy range. It has decreased from 14.31 (Mar 24) to 12.51, marking a decrease of 1.80.
• For Return On Assets (%), as of Mar 25, the value is 5.16. This value is within the healthy range. It has decreased from 5.34 (Mar 24) to 5.16, marking a decrease of 0.18.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.75. This value is within the healthy range. It has decreased from 0.77 (Mar 24) to 0.75, marking a decrease of 0.02.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.96. This value is within the healthy range. It has decreased from 0.97 (Mar 24) to 0.96, marking a decrease of 0.01.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.75. It has decreased from 0.82 (Mar 24) to 0.75, marking a decrease of 0.07.
• For Current Ratio (X), as of Mar 25, the value is 1.28. This value is below the healthy minimum of 1.5. It has decreased from 1.30 (Mar 24) to 1.28, marking a decrease of 0.02.
• For Quick Ratio (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. It has increased from 0.95 (Mar 24) to 0.97, marking an increase of 0.02.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 4. It has decreased from 1.65 (Mar 24) to 1.47, marking a decrease of 0.18.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 17.94. This value is below the healthy minimum of 20. It has increased from 14.65 (Mar 24) to 17.94, marking an increase of 3.29.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 10.56. This value is below the healthy minimum of 20. It has increased from 8.50 (Mar 24) to 10.56, marking an increase of 2.06.
• For Earning Retention Ratio (%), as of Mar 25, the value is 82.06. This value exceeds the healthy maximum of 70. It has decreased from 85.35 (Mar 24) to 82.06, marking a decrease of 3.29.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 89.44. This value exceeds the healthy maximum of 70. It has decreased from 91.50 (Mar 24) to 89.44, marking a decrease of 2.06.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 4.79. This value is within the healthy range. It has decreased from 4.87 (Mar 24) to 4.79, marking a decrease of 0.08.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.68. This value is below the healthy minimum of 3. It has decreased from 2.76 (Mar 24) to 2.68, marking a decrease of 0.08.
• For Enterprise Value (Cr.), as of Mar 25, the value is 42,601.67. It has increased from 35,828.33 (Mar 24) to 42,601.67, marking an increase of 6,773.34.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.59. This value exceeds the healthy maximum of 3. It has increased from 3.10 (Mar 24) to 3.59, marking an increase of 0.49.
• For EV / EBITDA (X), as of Mar 25, the value is 19.36. This value exceeds the healthy maximum of 15. It has increased from 16.25 (Mar 24) to 19.36, marking an increase of 3.11.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.73 (Mar 24) to 3.21, marking an increase of 0.48.
• For Retention Ratios (%), as of Mar 25, the value is 82.05. This value exceeds the healthy maximum of 70. It has decreased from 85.34 (Mar 24) to 82.05, marking a decrease of 3.29.
• For Price / BV (X), as of Mar 25, the value is 6.26. This value exceeds the healthy maximum of 3. It has increased from 5.87 (Mar 24) to 6.26, marking an increase of 0.39.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.73 (Mar 24) to 3.21, marking an increase of 0.48.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness